CASACOL EXPECTORANT SYRUP

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

METHOXYPHENAMINE HYDROCHLORIDE GUAIFENESIN SODIUM CITRATE

Available from:

Phoenix Healthcare Ltd

Dosage:

20/100/200 MG/5ml

Authorization date:

2011-06-23

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Casacol Expectorant Syrup,
Methoxyphenamine hydrochloride, 20mg/5ml
Guaiphenesin, 100mg/5ml
Sodium Citrate, 200mg/5ml
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Also contains Sorbitol (E420), Ponceau 4R (E124), Nipasept [methyl (E218), ethyl (E214) and propyl (E216)
Hydroxybenzoate]
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Syrup.
A pale red straw coloured liquid with a faint odour of cherry, contained in an amber glass bottle.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Indicated in the treatment of cough and congestion associated with the common cold, bronchitis, etc
Children aged 6-12 years: Casacol is indicated for second line use only.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
(A) ADULTS:
One or two 5ml spoonfuls 3 to 4 times daily.
(B) CHILDREN AGED 6 TO 12 YEARS:
5ml
3 to 4 times daily.
Maximum daily dose: 20ml syrup.
Not more than 4 doses should be given in any 24 hours. Do not exceed stated dose.
Use in children aged between 6-12 years should be under the supervision of a healthcare professional
(doctor/pharmacist). The duration of use should be restricted to no more than 5 days.
Use in children under 6 years is contra-indicated (see section 4.3).
Each 5 ml contains:
Methoxyphenamine hydrochloride
20
mg
Guaiphenesin
100
mg
Sodium citrate
200
mg
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 29/02/2012_
_CRN 2084351_
_page number: 1_
4.3 CONTRAINDICATIONS
1.
Coronary thrombosis, hypertension, hyperthyroidism, closed-angle glaucoma and urinary retention.
2.
Concurrent treatment with monoamine oxidase inhibitors, or within 10 days of stopping such treatment.
3.
Concurrent treatment with other sympath
                                
                                Read the complete document